Cove-SmithJ.R.: Analgesic nephropathy in the United Kingdom: incidence, clinical features and pathogenesis.J Clin Path1981; 34: 1255.
2.
NanraR.S., Stuart-TaylorJ., De LeonA.H., WhiteK.H.: Analgesic nephropathy: Etiology, clinical syndrome, and clinicopathologic correlations in Australia.Kidney Int1978; 13: 79.
3.
SchweingruberR.: Probleme der chronischen Vergiftung mit kombinierten Phenacetinpräparaten.Schweiz Med Wochenschr1955; 85: 1162.
4.
LeschkeE.: Die wichtigsten Vergiftungen.München, Lehmann1933 (cit. from Schweingruber [3]).
5.
GrimlundK.: Phenacetin and renal damage at a Swedish factory.Acta Med Scand174, Suppl 1963 405: 3.
6.
SpühlerO., ZollingerH.U.: Die chronische interstitielle Nephritis (The chronic interstitial nephritis).Helv Med Acta1950; 17: 564. (In German).
7.
ZollingerH.U., SpühlerO.: Die nicht-eitrige, chronische interstitielle Nephritis (The non-purulent chronic interstitial nephritis).Schweiz Ztschr Allg Pathol1950; 13: 807. (In German).
8.
SpühlerO., ZollingerH.U.: Die chronisch-interstitielle Nephritis (Chronic interstitial nephritis).Ztschr Klin Med1953; 151: 1. (In German).
9.
ZollingerH.U.: Chronische interstitielle Nephritis bei Abusus von phenacetinhaltigen Analgetica (Saridon usw) (Chronic interstitial nephritis and abuse of phenacetin compounds (Saridon etc.).Schweiz Med Wochenschr1955; 85: 746.
WoodburyD.M., FinglE.: Analgesic antipyretics, antiinflammatory agents, and drugs employed in the therapy of gout. In: The Pharmacological Basis of Therapeutics, 5th edition, edited by GoodmanL.S., GilmanA., GilmanA.G., KoelleG.B.New-York, MacMillan Publishing Cy, 1975, p 325 (344).
12.
FlowerR.J., MoncadaS., VaneJ.R.: Analgesic-antipyretics and anti-inflammatory agents: drugs employed in the treatment of gout. In: The Pharmacological Basis of Therapeutics, 7th edition, edited by Goodman GilmanA., GoodmanL.S., RailThW, MuradF.New-York, Mac Millan Publishing Cy, 1985, p 674 (695).
13.
DugganJ.M.: The analgesic syndrome.Aust NZ J Med1974; 4: 365.
14.
PrescottL.F.: Analgesic nephropathy: A rassment of the role of phenacetin and other analgesics.Drugs1982; 23: 75.
15.
HoffmeisterF.: Influence of intravenous selfadministered psychomotor stimulants on performance of rhesus monkeys in a multiple schedule paradigm.Psychopharmacology1980; 72: 41.
16.
HoffmeisterF.: Abhängigkeitspotential von Analgetika und Psychopharmatika (Dependence liability of analgesic and psychotropic drugs).Arzneim Forsch1984; 34(II): 1096. (In German, with a summary in English).
17.
Murray RobinM.: Genesis of analgesic nephropathy in the United Kingdom.Kidney Int1978; 13: 50.
18.
Anonymous: Analgesic associated kidney disease.National Institution of Health, Bethesda MD, Consensus Development Conference Statement, 1984; vol 5, nr 2.
19.
NanraR.S.: Nonsteroid anti-inflammatory analgesics - acute and chronic nephrotoxicity, 1985. (In press).
20.
Kincaid-SmithP.: Analgesic abuse and the kidney.Kidney Int1980; 17: 250.
21.
JacobsC., BroyerM., BrunnerF.P., BryngerH., DonckerwolckeR.A., KramerP., SelwoodN.H., WingA.J., BlakeP.H.: Combined report on regular dialysis and transplantation in Europe, XI, 1980.Proc Eur Dial Transplant-Eur Renal Ass1981; 18: 4.
22.
VanherweghemJ-L, Evan-AdinD.: Epidemiology of analgesic nephropathy in Belgium.Clin Nephrol1982; 17: 129.
23.
VanherweghemJ-L: Contribution to a workshop on analgesic nephropathy 22nd Congress Eur Dial Transplant-Eur Renal Ass Brussels 1985 (unpublished).
24.
BryngerH., BrunnerF.P., ChantlerC., DonckerwolckeR.A., JacobsC., KramerP., SelwoodN.H., WingA.J.: Combined report on regular dialysis and transplantation in Europe, X, 1979.Proc Eur Dial Transplant Ass1980; 17: 20.
25.
WingA.J., BrunnerF.P., BryngerH.O.H., JacobsC., KramerP.: Comparative review between dialysis and transplantation. In: Replacement of Renal Finction by Dialysis, 2nd edn., edited by DrukkerW., ParsonsF.M., MaherJ.F., Boston, The Hague, Dordrecht (The Netherl.), Lancaster (UK), Martinus Nijhoff Publishers, 1983, p 850 (858).
26.
WingA.J., BroyerM., BrunnerF.P., BryngerH., ChallahS., DonckerwolckeR.A., GretzN., JacobsC., KramerP., SelwoodN.H.: Combined report on regular dialysis and transplantation in Europe, XIII, 1982.Proc Eur Dial Transplant-Eur Renal Ass1983; 20: 38.
27.
PommerW., BrodaM., MolzahnM.: On the prevalence of analgesic nephropathy in the Federal Republic of Germany (FRG) and West-Berlin.Proc Symp on Analgesic Nephropathy, Antwerp, 1984 (unpublished copy of manuscript available from first author, address: Humboldt Krankenhaus, Dept. of Nephrology, Am Nordgraben, D-1000 Berlin 27).
28.
PommerW., MolzahnM.: Analgesic consumption in the Federal Republic of Germany (FRG): a permanent problem. Abstracts Symp on Drug-Induced Nephrotoxicity 1985, 3–17 (publ. by Dept of Nephrology/Hypertension, University Hospital Antwerp, B-2610 Wilrijk, Belgium.
29.
SchwarzA., PommerW., Kuhn-FreitagG., KellerF., MolzahnM., OffermannG.: Merkmale der terminalen Analgetika - Nephropathie (Features of terminal analgesic nephropathy).Schweiz Med Wochenschr1985; 15: 790.
30.
SchwarzA., FaberU., GlaeskeG, KellerF., OffermanG.: Analgesic nephropathy in West Germany (letter to the editor).Lancet1986; 1: 210.
DePalmaJ., WassanmillerJ., AbakurahA.: Phenacetin/aspirin nephritis as a cause of chronic renal failure.West Dial and Transplant Society (meeting at Las Vegas [Nov.] 1975).
33.
Murray ThomasG., GoldbergM.: Analgesic associated nephropathy in the USA: Epidemiologic, clinical and pathogenetic features.Kidney Int1978; 13: 64.
FurmanK.I., GalaskoP.T.F., MeyersA.M., RabkinR.: Posttransplantation analgesic dependence in patients who formerly suffered from analgesic nephropathy.Clin Nephrology1976; 5: 54.
36.
PendreighD.M., HeasmanN.H., HowittL.F., KennedyA.C., McDougallI.A., MacLeodM., RobsonJ.S., StewartW.K.: Survey of chronic renal failure in Scotland.Lancet1972; 1: 304.
37.
GaultM.H., WilsonD.R.: Analgesic nephropathy in Canada: Clinical syndrome, management, and outcome.Kidney Int1978; 13: 58.
38.
MihatschM.J., HoferH.O., GutzwilerF., BrunnerF.P., ZollingerH.U.: Phenacetinabusus I. Häufigkeit, Pro Kopf Verbrauch und Folgekosten (Phenacetin abuse I, Prevalence, pro capita consumption and cost).Schweiz Med Wochenschr1980; 110: 108. (In Ger man, with a summary in English).
39.
GaultM., RudwolT., EnglesW., DossetorJ: Syndrome associated with the abuse of analgesics.Ann Intern Med1968; 68: 906.
40.
Nordic Statistics on Medicines I, 1978-1980.Uppsala, Sweden, Nordic Council on Medicines, 1982.
41.
Nordic Statistics on Medicines (Nordic Drug Index with Classification and Defined Daily Doses) II, 1978-1980, Uppsala, Sweden, Nordic Council on Medicines, 1982.
42.
SillanpääM., KasanenA., ElonenA.: Changes of panorama in renal disease mortality in Finland after phenacetin restriction.Acta Med Scand1982; 212: 313.
43.
OttevangerE.A. (Philips-Duphar Inc., Weesp, The Netherlands): Personal communication to one of the authors, 1985.
44.
The Drug Consumption in Norway, edited by OydvinK., Norwegian Medicinal Depot, Oslo, Norway, 1984.
45.
MaherJ.F.: Analgesic nephropathy. Observations, interpretations, and perspective on the low incidence in America.Am J Med1984; 76: 345.
46.
DubachU.C.: Die Analgetikanephropathie (=AN). (The analgesic nephropathy).Therap Umschau1982; 39: 351. (In German with summaries in English and French).
47.
GloorF.J.: Changing concepts in pathogenesis and morphology of analgesic nephropathy as seen in Europe.Kidney Int1978; 13: 27.
48.
StewartJ.H.: Analgesic abuse and renal failure in Australasia.Kidney Int1978; 13: 72.
49.
NanraR.S.: Analgesic-induced renal disease1985. (In press).
50.
BrunnerF.P., BroyerM., Bryngertt, ChallahS., FassbinderW., OulèsR., RizzoniG., SelwoodN.H., WingA.J.: Combined report on regular dialysis and transplantation in Europe, XV, 1984.Proc Eur Dial Transplant-Eur Renal Ass1985; 22: 5.
51.
SchwarzA., KellerF., FaberU., PommerW., KemmerichB., LodeH., HuckaufH., OffermannG., MolzahnM.: Comparison between analgesic consumption in patients with analgesic nephropathy and controls.Kidney Int1985; 28: 229. (abstract).
Murray ThomasG., StolleyP.D., AnthonyJ.C., SchinnarR., Helper-SmithE., JeffreysJ.L.: Epidemiologic study of regular analgesic use and end-stage renal disease.Arch Intern Med1983; 143: 1687.
58.
McAnallyJ.F., WinchesterJ.F., SchreinerG.E.: Analgesic nephropathy. An uncommon cause of end-stage renal disease.Arch Int Med1983; 143: 1897.
59.
FellnerS., TuttleE.P.: The clinical syndrome of analgesic abuse.Arch Int Med1969; 124: 379.
60.
FreedmanL.R.: Urinary tract infection, pyelonephritis and other forms of chronic interstitial nephritis in Diseases of the Kidney, edited by StraussM.B., WeltL.G., 2nd edition, Boston MA, Little, Brown and Company, 1971, p 678.
61.
ClarksonA.J.R., LawrenceJ.R.: The clinical features of analgesic nephropathy. In: Renal Infection and Renal Scarring, edited by Kincaid-SmithP., FairleyK.F., Melbourne, Australia, 1970, p 375.
62.
GoldbergM.: Analgesic-associated nephropathy. In: Cecil, Textbook of Medicine, edited by WijngaardenJ.B., SmithL.H.Jr.Philadelphia, London etc.W.B. Saunders Cy, 1985, p 592.
63.
BockH.E.: Zur Klinik der Therapieschäden (Damage from therapy).Dtsch Med Wochenschr1957; 82: 1899. (In German).
64.
RickettsJ., NanraR.S.: Analgesic abuse in perpective1985, (in press).
65.
SchwarzA., FaberU., BornerK., KellerF., OffermannG., MolzahnM.: Reliability of drug history in analgesic users.Lancet1984; 2: 1163. (Letter to the editor).
66.
BrodieB.B., AxelrodJ.: The estimation of acetanilide and the metabolic products, aniline, N-acetyl p-aminophenol and p-aminophenol (free and total conjugated) in biological fluids and tissues.J Pharmacol Exp Ther1948; 94: 22.
67.
DubachU.C.: p-Aminophenol-Bestimmung im Urin als routine Method zur Erfassung der Phenacetineinnahme (The estimation of p-aminophenol in urine as routine check of ingestion of phenacetin).Dtsch Med Wochenschr1967; 92: 211.
68.
DubachU.C., RosnerB., LevyP.S., BaumelerH-R, MüllerA., PeyerA., EhrenspergerT., EttlinC.: Epidemiological study in Switzerland.Kidney Int1978; 13: 41.
PrescottL.F.: Analgesic nephropathy: A reassessment of the role of phenacetin and other analgesics.Drugs1982; 23: 75.
71.
HultengrenN., LagergrenC., LjungqvistA.: Carcinoma of the renal pelvis in renal papillary necrosis.Acta Chir Scand1965; 130: 314.
72.
BengtssonU., JohanssonS., AngervallL.: Malignancies of the urinary tract and their relation to analgesic abuse.Kidney Int1978; 13: 107.
73.
FokkensW.: Phenacetin abuse related to bladder cancer.Environ Res1979; 20: 192.
74.
PiperJ.M., TonasciaJ., MatanoskiG.M.: Heavy phenacetin use and bladder cancer in women aged 20 to 49 years.N Engl J Med1985; 313: 292.
75.
GonwaT.A., CorbettW.T., ScheyH.M., BuckalewV.M.: Analgesic associated nephropathy and transitional cell carcinoma of the urinary tract.Ann Int Med1980; 93: 249.
76.
KüngL.G.: Hypernephroides Karzinom und Karzinome der ableitenden Harnwege nach Phenacetinabusus (Hypernephroid carcinoma and carcinoma of the urinary tract after phenacetin abuse).Schweiz Med Wochenschr1976; 106: 47. (In German with a summary in English).
77.
MihatschM.J., ManzT., KnüsliC.: Phenacetin abuse III. Malignant urinary tract tumors in phenacetin abuse in Basle 1963-1977.Schweiz Med Wochenschr1980; 110: 225.
78.
MihatschM.J., KnüsliC.: Phenacetin abuse and malignant tumors. An autopsy study covering 25 years (1953-1977).Klin Wochenschr1982; 60: 1339.
79.
BachP.H., HardyT.L.: Relevance of animal models to analgesic associated renal papillary necrosis in humans.Kidney Int1985; 28: 605.
80.
KellerF., SchwarzA.: Analgesic dilemma in chronic hemodialysis patients.Pain1983; 17: 99.
81.
HeptinstallR.H.: Infarction, cortical necrosis and papillary necrosis, including the kidney in analgesic abuse. In: Pathology of the Kidney, 2nd edn, Vol I, edited by HeptinstallR.H., 1974, Boston, Little, Brown and Company, p 221 (257), Vol. II, p 630.
82.
ShelleyJ.H.: Pharmacological mechanisms of analgesic nephropathy.Kidney Int1978; 13: 15.
83.
PrescottL.F.: Effects of acetylsalicylic acid, phenacetin, paracetamol and caffeine on renal tubular epithelium.Lancet1965; 2: 91.
84.
PrescottL.F.: The nephrotoxicity of analgesics.J Pharm Pharmacol1966; 18: 331.
WeberM., BraunB., KöhlerH.: Ultrasonic findings in analgesic nephropathy.Nephron1985; 39: 216.
93.
SchoeppeW.: Indikation, Methoden und Ergebnisse der intermittrerenden Dauerdialysebehandlung (Indication, methods and results of regular dialysis treatment).Internist1983; 24: 494. (In German).
94.
Murray RobinM., LawsonD.H., LintonA.L.: Analgesic nephropathy: clinical syndrome and prognosis.Br Med J1971; 1: 479.
95.
KriklerD.M.: Paracetamol and the kidney.Br Med J1967; 2: 615.
96.
The Royal Australasian College of Physicians: Statement on analgesic nephropathy.Med J Aust1969; 1: 1388.
97.
Anonymous: Analgesics: a warning.Med J Aust1969; 1: 1364. (Editorial).
98.
The Royal Australasian College of Physicians: Statement on analgesic nephropathy.NZ Med J1969; 70: 39.
99.
KielholzP.: Ätiologie und Therapie der Analgeticaund Hypnoticasucht (Etiology and therapy of abuse of analgesics and hypnotics).Schweiz Med Wochenschr1954; 84: 753. (In German, with a summary in English).
100.
KielholzP.: Abusus und Sucht mit phenacetinhaltigen Kombinationspräparaten (Abuse and addiction of phenacetin mixtures).Schweiz Med Wochenschr1957; 87: 1131. (In German, with a summary in English).
101.
MoeschlinS.: Phenacetinsucht und -schäden (Phenacetin abuse and -damage).Schweiz Med Wochenschr 1956, 1957; 87.(In German, with a summary in English).
BurryA.F., HopkinsJ.: Phenacetin and analgesic nephropathy.Med J Aust1977; 1: 879.
108.
DisneyA.P.S., CorellR.L.: Report of the Australia and New Zealand combined dialysis and transplant registry.Med J Aust1981; 1: 117.
109.
WilsonD.R., GaultM.H.: Declining incidence of analgesic nephropathy in Canada.Can Med Ass J1982; 15: 501.
110.
Ask-UpmarkE.: Migraine as a deadly disease.Br Med J1960; 2: 823.
111.
FrithzG.: Phenacetin nephropathy in a mother and daughter.Acta Med Scand1967; 181: 529.
112.
Anonymous: Analgesic nephropathy.Br Med J1981; 282: 339. (Editorial).
113.
MacDonaldI.M., DumbleL.J., DoranT., BashirH., NanraR.S., Kincaid-SmithP.: Increased frequency of HLA-B12 in analgesic nephropathy.Aust NZ J Med1978; 8: 233.
114.
PrescottL.F., SansurM., LevinW., ConneyA.H.: The comparative metabolism of phenacetin and N-acetyl-p-aminophenol in man with particular reference to effects in the kidney.Clin Pharm Ther1968; 9: 605.
115.
KongI., DevonshireH.W., CooperM., SloanT.P., IdleJ.R., SmithR.L.: The Influences of oxydation phenotype on phenacetin metabolism and haemotoxicity.Br J Clin Pharmacol1981; 13: 275. (Abstract).
116.
WoolhouseN.M., AndohB., MahgoubA., SloanT.P., IdleJ.R., SmithR.L.: Debrisoquine hydroxylation polymorphism among Ghanaians and Caucasians.Clin Pharmacol Ther1979; 26: 584.
117.
NebertD.W.: Today's treatment: Clinical pharmacology: Possible clinical importance of genetic differences in drugs metabolism.Br Med J1981; 283: 537.
118.
GoldbergM.: Balkan nephropathy. In: Cecil, Textbook of Medicine, edited by WijngaardenJ.B., SmithL.H.Jr.Philadelphia, London etc.W.B. Saunders Cy, 1985 p 590.
119.
BrennerB.M., HostetterT.H., HumesD.H.: Balkan nephropathy. In: Harrison's Principles of Internal Medicine, 9th edn, edited by IsselbacherK.J., AdamsR.D., BraunwaldE., PetersdorfR.G., WilsonJ.D., London, Hamburg, Paris, Tokyo etc., McGraw-Hill Internat Book Comp., 1980 p 1338.
120.
FreedmannL.R.: Interstitial renal inflammation, including pyelonephritis and urinary tract infection. In: Strauss and Welt's Diseases of the Kidney, edited by EarlyL.E., GottschalkC.W., 3rd edn, Boston, Little Brown and Company, 1979, p 817.